The Richest Woman in the World: How Gina Rinehart Earns her Billions
America's 10 Highest-Paid CEOs of 2011 (and How They Earned It)
Lately, the Japanese pharma industry has flexed its M&A muscle, trying to find opportunities in global markets. And, the latest deal came this week: Dainippon Sumitomo Pharma agreed to shell out $2.6 billion for Sepracor Inc. (NASDAQ: SEPR). The deal is all-cash.
Why all the interest? There are several drivers. First, the strong yen has made deals fairly cheap. Next, the Japanese market is expected to be slow because of government mandates. And finally, Japanese pharma companies are coming up against expirations of major drugs.
Goldman Earnings Sink After Buffett Dividend
Johnson & Johnson's Income Falls 23%
Burberry Shares Leap on Sales Update
